triamcinolone acetonide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
steroids not used as glucocorticosteroids	2726	76-25-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nasacort triamcinolone acetonide aristicort allernaze	An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions. Molecular weight: 434.50 Formula: C24H31FO6 CLOGP: 2.21 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 93.06 ALOGS: -4.01 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nasacort
triamcinolone acetonide
aristicort
allernaze

An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.

Molecular weight: 434.50
Formula: C24H31FO6
CLOGP: 2.21
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 93.06
ALOGS: -4.01
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.11 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.26 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	23 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 4, 1960	FDA	APOTHECON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site atrophy	264.56	11.04	61	25317	482	46660202
Adrenal insufficiency	187.37	11.04	106	25272	13018	46647666
Soft tissue disorder	172.21	11.04	70	25308	4116	46656568
Skin atrophy	121.10	11.04	55	25323	4245	46656439
Non-infectious endophthalmitis	115.26	11.04	26	25352	184	46660500
Endophthalmitis	115.22	11.04	49	25329	3229	46657455
Pneumonia viral	101.33	11.04	56	25322	6568	46654116
Body height below normal	94.04	11.04	36	25342	1803	46658881
Synovitis	92.03	11.04	138	25240	60937	46599747
Arthritis	89.57	11.04	155	25223	77161	46583523
Human antichimeric antibody positive	88.51	11.04	32	25346	1364	46659320
Joint destruction	82.53	11.04	38	25340	3026	46657658
Fibromyalgia	80.18	11.04	99	25279	36364	46624320
Liver function test abnormal	80.17	11.04	112	25266	46375	46614309
Blood cholesterol increased	75.96	11.04	101	25277	39912	46620772
Juvenile idiopathic arthritis	74.59	11.04	39	25339	4093	46656591
Wheelchair user	72.84	11.04	38	25340	3970	46656714
Intraocular pressure increased	71.48	11.04	43	25335	5914	46654770
Obesity	70.79	11.04	60	25318	14146	46646538
Toxicity to various agents	67.73	11.04	16	25362	211750	46448934
Polyarthritis	62.82	11.04	41	25337	6501	46654183
Hypothalamic pituitary adrenal axis suppression	61.80	11.04	15	25363	151	46660533
Cushing's syndrome	57.48	11.04	20	25358	761	46659923
Bone density decreased	56.58	11.04	45	25333	9707	46650977
Antibody test positive	55.67	11.04	26	25352	2139	46658545
Bursitis infective	49.49	11.04	20	25358	1157	46659527
Retinal artery occlusion	49.41	11.04	21	25357	1381	46659303
Rhegmatogenous retinal detachment	48.87	11.04	11	25367	77	46660607
Urticarial vasculitis	46.86	11.04	15	25363	439	46660245
Psoriasis	46.76	11.04	120	25258	78484	46582200
Necrotising scleritis	46.28	11.04	12	25366	161	46660523
Ocular hypertension	45.89	11.04	17	25361	777	46659907
Visual acuity reduced	45.35	11.04	58	25320	22055	46638629
Herpes zoster	44.99	11.04	108	25270	67764	46592920
Death	44.66	11.04	71	25307	335477	46325207
Secondary adrenocortical insufficiency	44.28	11.04	17	25361	858	46659826
Adrenal suppression	42.90	11.04	17	25361	934	46659750
Retinal pigment epithelial tear	42.25	11.04	12	25366	231	46660453
Acute kidney injury	40.62	11.04	41	25337	235814	46424870
Maculopathy	40.35	11.04	19	25359	1592	46659092
Injection site discolouration	40.33	11.04	32	25346	6878	46653806
Eye infection toxoplasmal	39.83	11.04	12	25366	286	46660398
Postmenopausal haemorrhage	39.22	11.04	20	25358	1993	46658691
Drug specific antibody	35.11	11.04	16	25362	1244	46659440
Lipoatrophy	33.92	11.04	11	25367	336	46660348
Soft tissue swelling	33.48	11.04	14	25364	884	46659800
Macular degeneration	32.99	11.04	29	25349	7176	46653508
Intentional product use issue	32.86	11.04	82	25296	52698	46607986
Chorioretinopathy	32.57	11.04	13	25365	728	46659956
Atrophy	31.92	11.04	16	25362	1537	46659147
Gastroenteritis viral	31.73	11.04	44	25334	18075	46642609
Tractional retinal detachment	31.22	11.04	7	25371	48	46660636
Immunodeficiency	31.10	11.04	37	25341	13069	46647615
Leukopenia	30.48	11.04	94	25284	68249	46592435
Therapeutic product effect incomplete	29.89	11.04	102	25276	78051	46582633
Human anti-human antibody test	29.76	11.04	10	25368	342	46660342
Tenderness	28.09	11.04	40	25338	16841	46643843
Product contamination	25.49	11.04	10	25368	535	46660149
Eye inflammation	25.19	11.04	19	25359	3790	46656894
Hypopyon	24.83	11.04	11	25367	800	46659884
Dermatitis contact	24.52	11.04	26	25352	8097	46652587
Cushingoid	24.34	11.04	23	25355	6243	46654441
Drug abuse	24.16	11.04	3	25375	63405	46597279
Orbital infection	23.81	11.04	5	25373	24	46660660
Spinal cord infarction	23.41	11.04	8	25370	288	46660396
Renal impairment	23.01	11.04	6	25372	74366	46586318
Scleral thinning	22.88	11.04	5	25373	30	46660654
Red blood cell sedimentation rate increased	22.79	11.04	43	25335	22846	46637838
Skin discolouration	22.72	11.04	53	25325	32627	46628057
Therapy non-responder	22.59	11.04	61	25317	41091	46619593
Polypoidal choroidal vasculopathy	22.10	11.04	6	25372	97	46660587
Blindness	21.79	11.04	36	25342	17233	46643451
Muscle atrophy	21.42	11.04	21	25357	5963	46654721
Conjunctival ulcer	21.41	11.04	5	25373	42	46660642
Bradycardia	21.18	11.04	5	25373	66293	46594391
Keratitis fungal	20.95	11.04	6	25372	119	46660565
Overdose	20.86	11.04	15	25363	101964	46558720
Infection	20.78	11.04	134	25244	133458	46527226
Intentional overdose	20.55	11.04	5	25373	64939	46595745
Vitreous opacities	20.43	11.04	7	25371	254	46660430
Retinal scar	19.72	11.04	6	25372	148	46660536
Peripheral vascular disorder	19.60	11.04	20	25358	5957	46654727
Peripheral swelling	19.58	11.04	150	25228	157921	46502763
Thrombocytopenia	19.57	11.04	24	25354	126557	46534127
Exposure via breast milk	19.50	11.04	11	25367	1341	46659343
Epicondylitis	19.42	11.04	12	25366	1730	46658954
Acute febrile neutrophilic dermatosis	19.12	11.04	14	25364	2671	46658013
Injection site fibrosis	19.09	11.04	4	25374	19	46660665
Systemic lupus erythematosus	18.79	11.04	6	25372	65174	46595510
Pseudoendophthalmitis	18.45	11.04	4	25374	23	46660661
Detachment of retinal pigment epithelium	18.33	11.04	7	25371	348	46660336
Vitreous disorder	18.30	11.04	5	25373	83	46660601
Septic shock	18.27	11.04	71	25307	57822	46602862
Skin hypopigmentation	18.24	11.04	7	25371	353	46660331
Bone density increased	18.16	11.04	7	25371	357	46660327
Oral pain	18.10	11.04	41	25337	24756	46635928
Conjunctival haemorrhage	17.81	11.04	14	25364	2967	46657717
Intra-abdominal haematoma	17.59	11.04	11	25367	1620	46659064
Coma	17.50	11.04	5	25373	58344	46602340
Purpura senile	17.49	11.04	8	25370	627	46660057
Infective scleritis	17.48	11.04	3	25375	3	46660681
Eye infection fungal	17.28	11.04	5	25373	103	46660581
Retinal haemorrhage	17.23	11.04	17	25361	4866	46655818
Hypocalcaemia	17.07	11.04	42	25336	26743	46633941
Injection site abscess	16.82	11.04	9	25369	990	46659694
Injection site necrosis	16.77	11.04	10	25368	1352	46659332
Product use issue	16.64	11.04	98	25280	94546	46566138
Joint effusion	16.49	11.04	26	25352	11969	46648715
Pyloric abscess	16.26	11.04	3	25375	6	46660678
Staphylococcal infection	15.75	11.04	49	25329	35722	46624962
Rhinitis allergic	15.57	11.04	19	25359	6889	46653795
Drug specific antibody present	15.49	11.04	13	25365	3023	46657661
Rapidly progressive osteoarthritis	15.40	11.04	3	25375	9	46660675
Bronchiectasis	15.39	11.04	22	25356	9294	46651390
Pemphigus	15.31	11.04	3	25375	45271	46615413
Parakeratosis	15.08	11.04	5	25373	164	46660520
Arthritis bacterial	14.95	11.04	17	25361	5719	46654965
Chorioretinal folds	14.94	11.04	3	25375	11	46660673
Neutropenia	14.90	11.04	35	25343	143169	46517515
Retinal detachment	14.82	11.04	16	25362	5084	46655600
Dermatophytosis	14.82	11.04	5	25373	173	46660511
Infusion related reaction	14.80	11.04	20	25358	101188	46559496
Cardio-respiratory arrest	14.80	11.04	7	25371	59862	46600822
Impaired quality of life	14.74	11.04	13	25365	3229	46657455
Tarsal tunnel syndrome	14.21	11.04	7	25371	648	46660036
Short stature	14.20	11.04	5	25373	197	46660487
Retinal artery embolism	14.13	11.04	4	25374	76	46660608
Loss of personal independence in daily activities	14.06	11.04	65	25313	57118	46603566
General physical health deterioration	13.98	11.04	26	25352	115743	46544941
Diabetic ulcer	13.76	11.04	5	25373	216	46660468
Cardiac failure	13.62	11.04	14	25364	79934	46580750
Bursitis	13.60	11.04	32	25346	19810	46640874
Iridoschisis	13.59	11.04	3	25375	19	46660665
Upper respiratory tract infection bacterial	13.58	11.04	4	25374	88	46660596
Quality of life decreased	13.36	11.04	16	25362	5686	46654998
Skin depigmentation	13.28	11.04	7	25371	746	46659938
Resorption bone increased	13.17	11.04	8	25370	1119	46659565
Rotator cuff syndrome	13.10	11.04	23	25355	11560	46649124
Cardiac arrest	13.08	11.04	18	25360	90381	46570303
Injection site scar	13.05	11.04	7	25371	773	46659911
Steroid withdrawal syndrome	12.94	11.04	6	25372	485	46660199
Hyponatraemia	12.91	11.04	22	25356	101310	46559374
Seizure	12.86	11.04	30	25348	123024	46537660
Somnolence	12.77	11.04	43	25335	156478	46504206
Arthralgia	12.73	11.04	273	25105	364330	46296354
Ear discomfort	12.72	11.04	17	25361	6744	46653940
Pruritus	12.51	11.04	193	25185	242159	46418525
Retinal degeneration	12.45	11.04	6	25372	529	46660155
Necrotising retinitis	12.39	11.04	5	25373	288	46660396
Pancytopenia	12.24	11.04	17	25361	85041	46575643
Metabolic acidosis	12.24	11.04	3	25375	38777	46621907
Osteoporosis	12.16	11.04	49	25329	40559	46620125
Flushing	12.07	11.04	68	25310	64546	46596138
Hyperadrenocorticism	12.00	11.04	5	25373	313	46660371
Spinal cord ischaemia	11.96	11.04	3	25375	35	46660649
Incorrect route of product administration	11.86	11.04	27	25351	16356	46644328
C-reactive protein increased	11.84	11.04	63	25315	58527	46602157
Maternal exposure during pregnancy	11.54	11.04	24	25354	102525	46558159
Cataract subcapsular	11.44	11.04	6	25372	633	46660051
Phantom limb syndrome	11.35	11.04	4	25374	158	46660526
Gingival blister	11.32	11.04	3	25375	44	46660640
Glossodynia	11.26	11.04	5	25373	44368	46616316
Electrocardiogram QT prolonged	11.23	11.04	7	25371	51318	46609366
Joint injury	11.07	11.04	29	25349	19180	46641504
Cytomegalovirus chorioretinitis	11.05	11.04	8	25370	1499	46659185

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endophthalmitis	306.82	12.45	92	10467	3388	29938531
Visual acuity reduced	177.32	12.45	94	10465	15752	29926167
Non-infectious endophthalmitis	148.56	12.45	29	10530	152	29941767
Intraocular pressure increased	121.33	12.45	51	10508	5069	29936850
Ocular hypertension	111.55	12.45	30	10529	738	29941181
Maculopathy	84.63	12.45	25	10534	871	29941048
Uveitis	83.24	12.45	40	10519	5437	29936482
Chorioretinopathy	80.61	12.45	27	10532	1425	29940494
Choroiditis	77.56	12.45	23	10536	812	29941107
Eye infection toxoplasmal	65.41	12.45	15	10544	186	29941733
Macular oedema	63.94	12.45	27	10532	2711	29939208
Hypothalamic pituitary adrenal axis suppression	59.15	12.45	14	10545	201	29941718
Eye pain	57.07	12.45	41	10518	11748	29930171
Adrenal suppression	56.90	12.45	17	10542	616	29941303
Injection site atrophy	52.12	12.45	10	10549	47	29941872
Eye inflammation	51.51	12.45	20	10539	1617	29940302
Retinal artery occlusion	50.96	12.45	20	10539	1664	29940255
Infective scleritis	48.69	12.45	8	10551	11	29941908
Hypopyon	48.14	12.45	14	10545	461	29941458
Intentional product use issue	46.98	12.45	61	10498	36379	29905540
Glaucoma	46.87	12.45	28	10531	5880	29936039
Dermatitis contact	44.30	12.45	22	10537	3209	29938710
Macular fibrosis	41.62	12.45	12	10547	383	29941536
Diabetic retinal oedema	40.72	12.45	11	10548	275	29941644
Toxicity to various agents	40.29	12.45	7	10552	177176	29764743
Product contamination	39.76	12.45	13	10546	636	29941283
Cystoid macular oedema	39.07	12.45	13	10546	672	29941247
Retinal haemorrhage	36.39	12.45	22	10537	4721	29937198
Retinal artery embolism	35.20	12.45	7	10552	41	29941878
Necrotising retinitis	34.45	12.45	12	10547	713	29941206
Psoriasis	32.89	12.45	56	10503	42450	29899469
Product use issue	30.93	12.45	57	10502	45959	29895960
Skin hypopigmentation	30.87	12.45	9	10550	299	29941620
Symmetrical drug-related intertriginous and flexural exanthema	30.76	12.45	8	10551	172	29941747
Retinal detachment	30.14	12.45	20	10539	5040	29936879
Subretinal fluid	28.82	12.45	8	10551	222	29941697
Retinal pigment epithelial tear	27.88	12.45	8	10551	251	29941668
Uveitis-glaucoma-hyphaema syndrome	26.72	12.45	5	10554	20	29941899
Choroidal infarction	25.23	12.45	6	10553	88	29941831
Distal intestinal obstruction syndrome	25.17	12.45	8	10551	357	29941562
Visual field defect	25.14	12.45	17	10542	4419	29937500
Blindness	24.91	12.45	26	10533	12283	29929636
Adrenal insufficiency	24.66	12.45	24	10535	10439	29931480
Anaphylactic reaction	24.52	12.45	39	10520	27943	29913976
Cauda equina syndrome	24.49	12.45	8	10551	390	29941529
Vitreous opacities	24.23	12.45	7	10552	225	29941694
Expired product administered	23.81	12.45	14	10545	2855	29939064
Pseudoendophthalmitis	23.36	12.45	5	10554	44	29941875
Injection site calcification	22.80	12.45	4	10555	10	29941909
Completed suicide	22.44	12.45	4	10555	99488	29842431
Open globe injury	22.02	12.45	4	10555	13	29941906
Vitritis	20.34	12.45	8	10551	669	29941250
Spinal cord infarction	19.96	12.45	6	10553	222	29941697
Rhegmatogenous retinal detachment	19.89	12.45	4	10555	25	29941894
Anterior chamber inflammation	19.44	12.45	6	10553	243	29941676
Cataract subcapsular	19.34	12.45	6	10553	247	29941672
Retinal degeneration	19.03	12.45	6	10553	261	29941658
Central vision loss	18.92	12.45	4	10555	33	29941886
Cataract	18.53	12.45	30	10529	21805	29920114
Arthritis bacterial	18.18	12.45	14	10545	4450	29937469
Eye abscess	17.51	12.45	5	10554	154	29941765
Pain	17.30	12.45	112	10447	172529	29769390
Drug abuse	17.05	12.45	4	10555	82068	29859851
Arthritis infective	16.87	12.45	11	10548	2691	29939228
Amblyopia	16.74	12.45	4	10555	60	29941859
Cardiac arrest	16.59	12.45	6	10553	92844	29849075
Cushing's syndrome	15.80	12.45	6	10553	456	29941463
Lenticular opacities	15.73	12.45	5	10554	223	29941696
Vision blurred	15.71	12.45	41	10518	41775	29900144
Oesophageal perforation	15.67	12.45	6	10553	467	29941452
Mycobacterium kansasii infection	15.61	12.45	5	10554	229	29941690
Retinal oedema	15.08	12.45	6	10553	517	29941402
Application site pruritus	14.87	12.45	8	10551	1375	29940544
Intracranial hypotension	14.83	12.45	5	10554	269	29941650
Visual impairment	14.83	12.45	33	10526	30405	29911514
Subretinal fibrosis	14.73	12.45	4	10555	102	29941817
Incorrect route of product administration	14.66	12.45	19	10540	11296	29930623
Drug ineffective	14.42	12.45	183	10376	340204	29601715
Dermatitis	14.37	12.45	16	10543	8126	29933793
Rash	14.32	12.45	116	10443	191773	29750146
Vitrectomy	14.11	12.45	4	10555	120	29941799
Death	13.83	12.45	72	10487	357211	29584708
Cellulitis orbital	13.69	12.45	5	10554	341	29941578
Skin burning sensation	13.56	12.45	11	10548	3769	29938150
Skin exfoliation	13.47	12.45	27	10532	23145	29918774
Chondritis	13.18	12.45	4	10555	153	29941766
Dry skin	12.85	12.45	26	10533	22428	29919491
Cushingoid	12.84	12.45	9	10550	2478	29939441
Rash pruritic	12.76	12.45	26	10533	22546	29919373
Stomatitis	12.45	12.45	35	10524	37244	29904675

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:50857	anti-allergic agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Cerebral edema	indication	2032001
Lichen planus	indication	4776004	DOID:9201
Berylliosis	indication	8247009	DOID:10322
Psoriasis	indication	9014002	DOID:8893
Ankylosing spondylitis	indication	9631008	DOID:7147
Rheumatic heart disease	indication	23685000
Atopic dermatitis	indication	24079001	DOID:3310
Inflammatory bowel disease	indication	24526004	DOID:0050589
Multiple sclerosis	indication	24700007	DOID:2377
Severe adrenal insufficiency	indication	24867002
Sarcoidosis	indication	31541009	DOID:11335
Idiopathic thrombocytopenic purpura	indication	32273002	DOID:8924
Psoriasis with arthropathy	indication	33339001
Keloid scar	indication	33659008
Crohn's disease	indication	34000006
Tendinitis	indication	34840004	DOID:971
Erythema multiforme	indication	36715001
Contact dermatitis	indication	40275004	DOID:2773
Angioedema	indication	41291007	DOID:1558
Humoral hypercalcemia of malignancy	indication	47709007
Articular gout	indication	48440001	DOID:13189
Candidiasis of skin	indication	49883006
Seborrheic dermatitis	indication	50563003	DOID:8741
Edema of larynx	indication	51599000
Nephrotic syndrome	indication	52254009	DOID:1184
Lichen simplex chronicus	indication	53891004
Systemic lupus erythematosus	indication	55464009	DOID:9074
Allergic rhinitis	indication	61582004
Löffler's syndrome	indication	64936001	DOID:9503
Pemphigus	indication	65172003	DOID:9182
Granuloma annulare	indication	65508009	DOID:3777
Tenosynovitis	indication	67801009	DOID:970
Alopecia areata	indication	68225006	DOID:986
Rheumatoid arthritis	indication	69896004	DOID:7148
Transfusion reaction due to serum protein reaction	indication	72284000
Epicondylitis	indication	73583000	DOID:14087
Acquired thrombocytopenia	indication	74576004	DOID:11126
Sympathetic uveitis	indication	75315001	DOID:12029
Thyroiditis	indication	82119001	DOID:7166
Bursitis	indication	84017003	DOID:2965
Autoimmune disease	indication	85828009
Infection by larvae of Trichinella spiralis	indication	88264003
Pruritus ani	indication	90446007
Acute lymphoid leukemia	indication	91857003	DOID:9952
Subacute bursitis	indication	109298000
Dermatitis herpetiformis	indication	111196000	DOID:8505
Hodgkin's disease	indication	118599009
Non-Hodgkin's lymphoma	indication	118601006
Mycosis fungoides	indication	118618005
Uveitis	indication	128473001	DOID:13141
Aspiration pneumonitis	indication	155597006
Asthma	indication	195967001	DOID:2841
Discoid lupus erythematosus	indication	200938002
Plaque psoriasis	indication	200965009
Transplanted organ rejection	indication	213148006
Scalp psoriasis	indication	238608008
Adrenogenital disorder	indication	267395000	DOID:0050811
Pruritus of genital organs	indication	267802000
Eruption of skin	indication	271807003	DOID:0050486
Seasonal allergic rhinitis	indication	367498001
Disorder of eye	indication	371405004	DOID:5614
Adrenal cortical hypofunction	indication	386584007	DOID:10493
Erythroderma	indication	399992009
Primary cutaneous T-cell lymphoma	indication	400122007
Asthma management	indication	406162001
Autoimmune hemolytic anemia	indication	413603009	DOID:718
Giant cell arteritis	indication	414341000	DOID:13375
Synovitis	indication	416209007	DOID:2703
Aphthous ulcer of mouth	indication	426965005	DOID:9663
Post traumatic osteoarthritis	indication	699262001
Severe Ocular Inflammation	indication
Chronic Non-Allergic Rhinitis	indication
Cystic Aponeurosis Tumor	indication
Systemic Dermatomyositis	indication
Allergic Rhinitis Prevention	indication
Gingival Disorders	indication
Erythroblastic Anemia	indication
Transfusion Reaction Urticaria	indication
Vitrectomy Adjunct to Enhance Visualization	indication
Synovitis due to Osteoarthritis	indication
Respiratory distress syndrome in the newborn	off-label use	46775006
Congenital hypoplastic anemia	off-label use	88854002	DOID:1339
Severe chronic obstructive pulmonary disease	off-label use	313299006
Neonatal Bronchopulmonary Dysplasia	off-label use
Infection by Strongyloides	contraindication	1214006	DOID:10955
Mycosis	contraindication	3218000	DOID:1564
Ocular hypertension	contraindication	4210003	DOID:9282
Gastritis	contraindication	4556007	DOID:4029
Inactive tuberculosis	contraindication	11999007
Epistaxis	contraindication	12441001
Peptic ulcer	contraindication	13200003	DOID:750
Hypercholesterolemia	contraindication	13644009
Measles	contraindication	14189004	DOID:8622
Disease caused by parasite	contraindication	17322007
Cirrhosis of liver	contraindication	19943007	DOID:5082
Arginase deficiency	contraindication	23501004	DOID:9278
Glaucoma	contraindication	23986001	DOID:1686
Acute tuberculosis	contraindication	25629007
Fungal infection of eye	contraindication	31194008
Immunosuppression	contraindication	38013005
Hypertensive disorder	contraindication	38341003	DOID:10763
Infectious disease	contraindication	40733004
Hypothyroidism	contraindication	40930008	DOID:1459
Herpes zoster keratoconjunctivitis	contraindication	42448002
Hypokalemia	contraindication	43339004
Chronic heart failure	contraindication	48447003
Tuberculosis of eye	contraindication	49107007
Cerebral malaria	contraindication	53622003	DOID:14069
Tuberculosis	contraindication	56717001
Congenital hyperammonemia, type I	contraindication	62522004
Osteoporosis	contraindication	64859006	DOID:11476
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Hypopituitarism	contraindication	74728003	DOID:9406
Candidiasis of mouth	contraindication	79740000	DOID:14262
Perforation of nasal septum	contraindication	80142000
Hyperglycemia	contraindication	80394007	DOID:4195
Open-angle glaucoma	contraindication	84494001	DOID:1067
Bacterial infectious disease	contraindication	87628006
Muscle atrophy	contraindication	88092000	DOID:767
Herpes simplex	contraindication	88594005	DOID:8566
Operation on nose	contraindication	88733004
Bilateral cataracts	contraindication	95722004
Seizure disorder	contraindication	128613002
Disorder of muscle	contraindication	129565002	DOID:423
Ophthalmic herpes simplex	contraindication	186542001
Anastomosis of intestine	contraindication	235407009
Disease of liver	contraindication	235856003	DOID:409
Telangiectasia disorder	contraindication	247479008
Edema	contraindication	267038008
Pathological fracture	contraindication	268029009
Diverticulitis of gastrointestinal tract	contraindication	271366000
Cerebral trauma	contraindication	275382005
Oral infection	contraindication	275393007
Varicella-zoster virus infection	contraindication	309465005
Viral eye infection	contraindication	312132001
Osteopenia	contraindication	312894000
Skin irritation	contraindication	367466007
Herpes zoster keratitis	contraindication	397573005
Avascular necrosis of bone	contraindication	397758007	DOID:10159
Citrullinemia	contraindication	398680004	DOID:9273
Atrophoderma	contraindication	399979006
Traumatic rupture of tendon	contraindication	415749005
Exposure to varicella	contraindication	444453009
Nasal Septal Ulcers	contraindication
Ornithine Carbamyltransferase Deficiency	contraindication
Periodontal Infections	contraindication
Nasal Candidiasis	contraindication
Nasal Trauma	contraindication
Oropharyngeal Candidiasis	contraindication
Uncontrolled Bacterial Infections	contraindication
Untreated Fungal Infection	contraindication
Arginosuccinate Lyase Deficiency	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.08	acidic
pKa2	11.78	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	EC50	9.30	WOMBAT-PK	CHEMBL
Annexin A1	Cytosolic other	P04083	ANXA1_HUMAN				WOMBAT-PK
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	7.64	DRUG MATRIX

External reference:

ID	Source
D00983	KEGG_DRUG
4017597	VANDF
C2608734	UMLSCUI
CHEBI:71418	CHEBI
1TA	PDB_CHEM_ID
CHEMBL1504	ChEMBL_ID
6436	PUBCHEM_CID
D014222	MESH_DESCRIPTOR_UI
F446C597KA	UNII
2867	IUPHAR_LIGAND_ID
DB00620	DRUGBANK_ID
10761	RXNORM
2967	MMSL
5614	MMSL
6440	MMSL
002189	NDDF
395913005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KENULLLOG-40	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0293	INJECTION, SUSPENSION	40 mg	INTRAMUSCULAR	NDA	21 sections
KENULLLOG-80	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0315	INJECTION, SUSPENSION	80 mg	INTRAMUSCULAR	NDA	21 sections
KENULLLOG-10	HUMAN PRESCRIPTION DRUG LABEL	1	0003-0494	INJECTION, SUSPENSION	10 mg	INTRA-ARTICULAR	NDA	22 sections
TRIESENCE	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0543	INJECTION, SUSPENSION	40 mg	OPHTHALMIC	NDA	23 sections
Good Sense Nasal Allergy	HUMAN OTC DRUG LABEL	1	0113-0443	SPRAY, METERED	55 ug	NULLSAL	ANDA	16 sections
basic care nasal allergy	HUMAN OTC DRUG LABEL	1	0113-7005	SPRAY, METERED	55 ug	NULLSAL	ANDA	15 sections
triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0002	CREAM	5 mg	TOPICAL	ANDA	17 sections
triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0003	CREAM	0.25 mg	TOPICAL	ANDA	17 sections
triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0004	CREAM	1 mg	TOPICAL	ANDA	17 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0005	OINTMENT	0.25 mg	TOPICAL	ANDA	19 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0006	OINTMENT	1 mg	TOPICAL	ANDA	19 sections
Nystatin and Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0081	CREAM	1 mg	TOPICAL	ANDA	16 sections
Nystatin and Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0089	OINTMENT	1 mg	TOPICAL	ANDA	19 sections
triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0336	LOTION	0.25 mg	TOPICAL	ANDA	17 sections
triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0337	LOTION	1 mg	TOPICAL	ANDA	17 sections
TRIDERM	HUMAN PRESCRIPTION DRUG LABEL	1	0316-0165	CREAM	0.25 mg	TOPICAL	ANDA	18 sections
TRIDERM	HUMAN PRESCRIPTION DRUG LABEL	1	0316-0170	CREAM	1 mg	TOPICAL	ANDA	18 sections
TRIDERM	HUMAN PRESCRIPTION DRUG LABEL	1	0316-0175	CREAM	5 mg	TOPICAL	ANDA	18 sections
Nystatin and Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	2	0316-0223	CREAM	1 mg	TOPICAL	ANDA	18 sections
Allergy Nasal	HUMAN OTC DRUG LABEL	1	0363-0811	SPRAY, METERED	55 ug	NULLSAL	ANDA	16 sections
Triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0440-0251	CREAM	1 mg	TOPICAL	ANDA	18 sections
Triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0440-0317	CREAM	0.25 mg	TOPICAL	ANDA	17 sections
Triamcinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0440-0318	CREAM	5 mg	TOPICAL	ANDA	17 sections
Nystatin and Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0150	CREAM	1 mg	TOPICAL	ANDA	11 sections
Nystatin and Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0155	OINTMENT	1 mg	TOPICAL	ANDA	11 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-0241	INJECTION, SUSPENSION	40 mg	INTRA-ARTICULAR	ANDA	20 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-0243	INJECTION, SUSPENSION	40 mg	INTRA-ARTICULAR	ANDA	20 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-0245	INJECTION, SUSPENSION	40 mg	INTRA-ARTICULAR	ANDA	20 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0225	CREAM	1 mg	TOPICAL	ANDA	18 sections
Triamcinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0226	CREAM	0.25 mg	TOPICAL	ANDA	18 sections